Mechlorethamine

"Mechlorethamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.

Descriptor ID	D008466
MeSH Number(s)	D02.455.526.728.650.529
Concept/Terms	Mechlorethamine Mechlorethamine Chlormethine Bis(2-chloroethyl)methylamine Mustine Nitrogen Mustard Chlorethazine Methylchlorethamine Cloramin Cloramin Embichin Embichin Mechlorethamine Hydrochloride Mechlorethamine Hydrochloride Hydrochloride, Mechlorethamine Mechlorethamine Hydrochloride N-Oxide Mechlorethamine Hydrochloride N-Oxide Hydrochloride N-Oxide, Mechlorethamine Mechlorethamine Hydrochloride N Oxide N-Oxide, Mechlorethamine Hydrochloride NSC-762 NSC-762 NSC 762 NSC762 Mechlorethamine Oxide Mechlorethamine Oxide Mitomen Mitomen Mustargen Mustargen Nitrogranulogen Nitrogranulogen Nitromin Nitromin NSC-10107 NSC-10107 NSC 10107 NSC10107 Caryolysine Caryolysine Mechlorethamine N-Oxide Mechlorethamine N-Oxide Mechlorethamine N Oxide Nitrogen Mustard N-Oxide N-Oxide, Nitrogen Mustard Nitrogen Mustard N Oxide

Below are MeSH descriptors whose meaning is more general than "Mechlorethamine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Mechlorethamine [D02.455.526.728.650.529]

Below are MeSH descriptors whose meaning is related to "Mechlorethamine".

Below are MeSH descriptors whose meaning is more specific than "Mechlorethamine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mechlorethamine" by people in this website by year, and whether "Mechlorethamine" was a major or minor topic of these publications.

Bar chart showing 4 publications over 4 distinct years, with a maximum of 1 publications in 1997 and 2012 and 2018 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2012	1	0	1
2018	1	0	1
2022	0	1	1

Below are the most recent publications written about "Mechlorethamine" by people in Profiles.

Correia E, Krishnasamy S, Suriano JG, Shi W, Alpdogan SO, Sahu J, Porcu P, Nikbakht N. Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):581-588.

View in: PubMed
Jennings T, Duffy R, Gochoco A, Knoblauch K, Shi W, Alpdogan SO, Porcu P, Werner-Wasik M, Sahu J. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol. 2019 Feb; 8(1):13.

View in: PubMed
Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer--the example of mechlorethamine. N Engl J Med. 2012 Dec 27; 367(26):2461-3.

View in: PubMed
Golden MA, Vaughn DJ, Crooks GW, Holland GA, Bavaria JE. Aortic dissection in a patient receiving chemotherapy for Hodgkin's disease--a case report. Angiology. 1997 Dec; 48(12):1063-5.

View in: PubMed
Lanzillo JH, Moylan DJ, Mohiuddin M, Kramer S. Radiotherapy of stage I and II Hodgkin disease with inguinal presentation. Radiology. 1985 Jan; 154(1):213-5.

View in: PubMed
Tester WJ, Kinsella TJ, Waller B, Makuch RW, Kelley PA, Glatstein E, DeVita VT. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984 Jul; 2(7):762-9.

View in: PubMed
Cooper MR, Pajak TF, Gottlieb AJ, Glicksman AS, Nissen N, Richards F, Bloomfield C, Holland JF. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol. 1984 Jul; 2(7):748-55.

View in: PubMed
Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15; 46(4):654-62.

View in: PubMed
Nissen NI, Pajak TF, Glidewell O, Pedersen-Bjergaard J, Stutzman L, Falkson G, Cuttner J, Blom J, Leone L, Sawitsky A, Coleman M, Haurani F, Spurr CL, Harley JB, Seligman B, Cornell C, Henry P, Senn HJ, Brunner K, Martz G, Maurice P, Bank A, Shapiro L, James GW, Holland JF. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Cancer. 1979 Jan; 43(1):31-40.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement